Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3zeta, eGFP)

Mfr.No.

78775

Description

The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor), containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains. This construct also includes an IRES- enhanced green fluorescent protein (eGFP) sequence downstream of anti-CD19 CAR cassette to facilitate analysis and sorting of transduced cells.

Note: This product transduces the same anti-CD19 CAR construct (CD19 ScFv-CD8-4-1BB-CD3ζ) as other available anti-CD19 CAR Lentiviruses (BPS Bioscience #78600, 78601 and 78602), but differ in key aspects. This product contains an eGFP reporter/selection marker so the transduced cells can be sorted based on eGFP expression. Please see table below.

Product SKU	Self-Inactivation (SIN)	Selection Marker
BHV18200003	no	puromycin
BHV18200006	yes	no
BHV18200004	yes	puromycin
BHV18200005	yes	eGFP

CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Applications Range

Positive control for anti-CD19 CAR evaluation in T cells.
Transduction optimization experiments.
Generate anti-CD19 CAR-T cells (for research use only, not for therapeutic purposes).

Storage

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.

Shipping

-80°C

No Description Available.

No Description Available.

Have you used this product?

Rate it now..!!

SKU	Supplier No.	Size	Your price	Quantity
BHV18200005	78775	50 µl	$1350		Add to Cart

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3zeta, eGFP)

Contact us to order

Tel

Email

Contact us to order

Tel

Email

Reviews of Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3zeta, eGFP)

Rate it now..!!